Levin, V A <br/><br/>
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Oct 2000 
 - 3878-84 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Brain Neoplasms--drug therapy<br/>Cisplatin--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Eflornithine--administration & dosage<br/>Female<br/>Glioblastoma--drug therapy<br/>Humans<br/>Lomustine--administration & dosage<br/>Male<br/>Middle Aged<br/>Procarbazine--administration & dosage<br/>Prospective Studies<br/>Time Factors<br/>Vincristine--administration & dosage<br/>Vindesine--administration & dosage